Objective:To explore the application effect of the combination of formoterol,beclomethasone and glycopyrronium bro-mide in the treatment of patients with chronic obstructive pulmonary disease.Methods:104 patients with chronic obstructive pulmonary disease were selected and divided into 52 cases of the control group(adopting the double combination treatment of gronethammonium bromide+formoterol)and 52 cases of the observation group(on the basis of the control group+beclomethasone treatment)accord-ing to different treatment methods.All treatments lasted for 3 months.The treatment efficacy,pulmonary function indicators[forced ex-piratory volume in one second(FEV1),forced vital capacity(FVC)],arterial blood gas indicators[partial pressure of oxygen(PaO2),pH,partial pressure of carbon dioxide(PaCO2)],quality of life[6-minute walking distance and St.George's Respiratory Questionnaire(SGRQ)score],inflammatory factor[interleukin-6(IL-6),tumor necrosis factor alpha(TNF-α),and C-reactive pro-tein(CRP)]levels before and 3 months after treatment,and record the occurrence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the observation group was higher than that in the control group(98.28%vs.84.62%,P<0.05).After 3 months of treatment,the FEV1,FVC,PaO2,pH,and 6-minute walking distance in both groups increased compared to before treatment(P<0.05),and the observation group was higher than the control group(P<0.05).PaCO2,SGRQ score,IL-6,TNF-α,and CRP were reduced compared to before treatment(P<0.05),and the observation group was lower than the con-trol group(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P＞0.05).Con-clusion:The combination of formoterol,beclomethasone and griseofulvin in the treatment of patients with chronic obstructive pulmonary disease is effective in improving lung function,arterial blood gas,reducing inflammatory response and improving quality of life.